AR035586A1 - Composicion de vacuna, equipo, metodos para incrementar la respuesta inmune, uso de un derivado de 1h-imidazo(4,5-c)quinolin-4-amina en la fabricacion de un medicamento, y combinacion de componentes para la administracion separada, secuencial o concomitante para el uso en la vacunacion de adn - Google Patents
Composicion de vacuna, equipo, metodos para incrementar la respuesta inmune, uso de un derivado de 1h-imidazo(4,5-c)quinolin-4-amina en la fabricacion de un medicamento, y combinacion de componentes para la administracion separada, secuencial o concomitante para el uso en la vacunacion de adnInfo
- Publication number
- AR035586A1 AR035586A1 ARP010104453A ARP010104453A AR035586A1 AR 035586 A1 AR035586 A1 AR 035586A1 AR P010104453 A ARP010104453 A AR P010104453A AR P010104453 A ARP010104453 A AR P010104453A AR 035586 A1 AR035586 A1 AR 035586A1
- Authority
- AR
- Argentina
- Prior art keywords
- quinolin
- imidazo
- manufacture
- derivative
- vaccine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Una composición de vacuna, caracterizada porque comprende (i) un componente adyuvante que comprende un derivado de 1H-imidazo[4,5-c]quinolin-4-amina y (ii) un componente inmunogénico que comprende una secuencia nucleotídica que codifica para un péptido o proteína antigénica asociada con un estado de enfermedad. Reivindicación 18: El uso de un derivado de 1H-imidazo[4,5-c]quinolin-4-amina en la fabricación de un medicamento para aumentar las respuestas inmunes iniciadas por un péptido antigénico, dicho péptido es expresado como resultado de la administración a un mamífero, de una secuencia nucleotídica que codifica para dicho péptido.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0023008.6A GB0023008D0 (en) | 2000-09-20 | 2000-09-20 | Improvements in vaccination |
Publications (1)
Publication Number | Publication Date |
---|---|
AR035586A1 true AR035586A1 (es) | 2004-06-16 |
Family
ID=9899764
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010104453A AR035586A1 (es) | 2000-09-20 | 2001-09-20 | Composicion de vacuna, equipo, metodos para incrementar la respuesta inmune, uso de un derivado de 1h-imidazo(4,5-c)quinolin-4-amina en la fabricacion de un medicamento, y combinacion de componentes para la administracion separada, secuencial o concomitante para el uso en la vacunacion de adn |
Country Status (25)
Country | Link |
---|---|
US (3) | US20040076633A1 (es) |
EP (1) | EP1318835B1 (es) |
JP (1) | JP2004509150A (es) |
KR (1) | KR100876263B1 (es) |
CN (1) | CN1197620C (es) |
AR (1) | AR035586A1 (es) |
AT (1) | ATE401097T1 (es) |
AU (2) | AU8790801A (es) |
BR (1) | BR0113982A (es) |
CA (1) | CA2422863A1 (es) |
CZ (1) | CZ2003792A3 (es) |
DE (1) | DE60134866D1 (es) |
ES (1) | ES2309086T3 (es) |
GB (1) | GB0023008D0 (es) |
HK (1) | HK1057700A1 (es) |
HU (1) | HUP0301180A3 (es) |
IL (1) | IL154947A0 (es) |
MX (1) | MXPA03002453A (es) |
MY (1) | MY138978A (es) |
NO (1) | NO20031274L (es) |
NZ (1) | NZ524792A (es) |
PL (1) | PL360895A1 (es) |
TW (1) | TWI287453B (es) |
WO (1) | WO2002024225A1 (es) |
ZA (1) | ZA200302231B (es) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
DE69932717T2 (de) | 1998-05-22 | 2007-08-09 | Ottawa Health Research Institute, Ottawa | Methoden und produkte zur induzierung mukosaler immunität |
US6677347B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
CA2484044A1 (en) * | 2002-03-19 | 2003-10-02 | Powdermed Limited | Imidazoquinolineamines as adjuvants in hiv dna vaccination |
GB0206461D0 (en) * | 2002-03-19 | 2002-05-01 | Glaxo Group Ltd | Improvements in vaccination |
AU2003216851B2 (en) * | 2002-03-19 | 2008-04-17 | Powderject Research Limited | Imidazoquinoline adjuvants for vaccines |
CN1671412B (zh) * | 2002-08-15 | 2010-05-26 | 3M创新有限公司 | 免疫刺激组合物及刺激免疫反应的方法 |
NZ540826A (en) | 2002-12-20 | 2008-07-31 | 3M Innovative Properties Co | Aryl / hetaryl substituted imidazoquinolines |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
US7648997B2 (en) * | 2003-08-12 | 2010-01-19 | Coley Pharmaceutical Group, Inc. | Hydroxylamine substituted imidazoquinolines |
CA2536249A1 (en) * | 2003-08-25 | 2005-03-10 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
JP2007504145A (ja) * | 2003-08-25 | 2007-03-01 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫刺激性の組み合わせおよび治療 |
NZ545412A (en) | 2003-08-27 | 2008-12-24 | Coley Pharm Group Inc | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
US20050054665A1 (en) * | 2003-09-05 | 2005-03-10 | 3M Innovative Properties Company | Treatment for CD5+ B cell lymphoma |
BRPI0414856A (pt) | 2003-10-03 | 2006-11-21 | 3M Innovative Properties Co | imidazoquinolinas alcóxi-substituìdas |
US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
US20090075980A1 (en) * | 2003-10-03 | 2009-03-19 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and Analogs Thereof |
US7897767B2 (en) | 2003-11-14 | 2011-03-01 | 3M Innovative Properties Company | Oxime substituted imidazoquinolines |
CN1906192A (zh) * | 2003-11-14 | 2007-01-31 | 3M创新有限公司 | 羟胺取代的咪唑环化合物 |
KR101130928B1 (ko) | 2003-11-25 | 2012-04-12 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 치환된 이미다조 고리 시스템 및 방법 |
EP1701955A1 (en) * | 2003-12-29 | 2006-09-20 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
WO2005066169A2 (en) * | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides |
US8697873B2 (en) * | 2004-03-24 | 2014-04-15 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
US8017779B2 (en) * | 2004-06-15 | 2011-09-13 | 3M Innovative Properties Company | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
WO2006009832A1 (en) * | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
WO2006065280A2 (en) * | 2004-06-18 | 2006-06-22 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods |
US8026366B2 (en) * | 2004-06-18 | 2011-09-27 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
WO2006038923A2 (en) * | 2004-06-18 | 2006-04-13 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
WO2006026760A2 (en) * | 2004-09-02 | 2006-03-09 | 3M Innovative Properties Company | 1-amino imidazo-containing compounds and methods |
DE102004049223A1 (de) | 2004-10-08 | 2006-04-20 | Johannes-Gutenberg-Universität Mainz | Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung |
US20070243215A1 (en) * | 2004-10-08 | 2007-10-18 | Miller Richard L | Adjuvant for Dna Vaccines |
JP2008523076A (ja) * | 2004-12-08 | 2008-07-03 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫調節性の組成物、合剤、および方法 |
ES2392648T3 (es) | 2004-12-30 | 2012-12-12 | 3M Innovative Properties Company | Compuestos quirales sustituidos que contienen un núcleo 1,2-imidazo-4,5-c condensado |
JP5543068B2 (ja) * | 2004-12-30 | 2014-07-09 | スリーエム イノベイティブ プロパティズ カンパニー | キラル縮合[1,2]イミダゾ[4,5−c]環状化合物 |
SI1830876T1 (sl) * | 2004-12-30 | 2015-08-31 | Meda Ab | Uporaba imikvimoda za zdravljenje kožnih metastaz, ki izhajajo iz rakavega tumorja dojke |
JP2008530022A (ja) | 2005-02-04 | 2008-08-07 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 免疫反応調節物質を含む水性ゲル処方物 |
WO2006086634A2 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
EP1869043A2 (en) | 2005-04-01 | 2007-12-26 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridine-1,4-diamines and analogs thereof |
JP2008538550A (ja) | 2005-04-01 | 2008-10-30 | コーリー ファーマシューティカル グループ,インコーポレイテッド | ウイルス感染および腫瘍性疾患を処置するためのサイトカイン生合成の調節因子としての1−置換ピラゾロ(3,4−c)環状化合物 |
EP1931352B1 (en) | 2005-08-22 | 2016-04-13 | The Regents of The University of California | Tlr agonists |
EA200800782A1 (ru) * | 2005-09-09 | 2008-08-29 | Коли Фармасьютикал Груп, Инк. | ПРОИЗВОДНЫЕ АМИДА И КАРБАМАТА N-{2-[4-АМИНО-2-(ЭТОКСИМЕТИЛ)-1Н-ИМИДАЗОЛО[4,5-c]ХИНОЛИН-1-IL]-1,1-ДИМЕТИЛЭТИЛ}МЕТАНСУЛЬФОНАМИДА И СПОСОБЫ |
ZA200803029B (en) * | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
JP5247458B2 (ja) * | 2005-11-04 | 2013-07-24 | スリーエム・イノベイティブ・プロパティーズ・カンパニー | ヒドロキシ及びアルコキシ置換1h−イミダゾキノリン及び方法 |
WO2007100634A2 (en) | 2006-02-22 | 2007-09-07 | 3M Innovative Properties Company | Immune response modifier conjugates |
US8329721B2 (en) * | 2006-03-15 | 2012-12-11 | 3M Innovative Properties Company | Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods |
WO2007106852A2 (en) | 2006-03-15 | 2007-09-20 | Coley Pharmaceutical Group, Inc. | Substituted fused[1,2]imidazo[4,5-c] ring compounds and methods |
EP2010201A1 (en) * | 2006-04-25 | 2009-01-07 | Intercell AG | Hcv vaccinations |
US20090060928A1 (en) * | 2006-05-26 | 2009-03-05 | Jean-Claude Bystryn | Topical Toll Like Receptor Ligands as Vaccine Adjuvants |
CA2653941C (en) | 2006-05-31 | 2013-01-08 | The Regents Of The University Of California | Substituted amino purine derivatives and uses thereof |
JP2009541236A (ja) * | 2006-06-20 | 2009-11-26 | トランジェーヌ、ソシエテ、アノニム | 組換えウイルスワクチン |
CA2655933C (en) | 2006-06-23 | 2014-09-09 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in cancer |
WO2008008432A2 (en) * | 2006-07-12 | 2008-01-17 | Coley Pharmaceutical Group, Inc. | Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods |
CN100450484C (zh) * | 2006-10-11 | 2009-01-14 | 北京科信必成医药科技发展有限公司 | 一种咪喹莫特混悬溶液及其凝胶剂 |
PT2510946E (pt) | 2007-02-07 | 2015-11-23 | Univ California | Conjugados de agonistas sintéticos de tlr e suas utilizações |
JP5755839B2 (ja) * | 2007-02-15 | 2015-07-29 | マンカインド コーポレイション | T細胞応答の増強方法 |
US8709445B2 (en) | 2007-07-31 | 2014-04-29 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Vaccination with killed but metabolically active (KBMA) protozoans with toll-like receptor agonists |
ES2664753T3 (es) | 2007-12-07 | 2018-04-23 | Glaxosmithkline Biologicals Sa | Composiciones de inducción de respuestas inmunes |
CA3050455A1 (en) | 2008-11-03 | 2010-06-03 | Adc Therapeutics Sa | Antibodies that specifically block the biological activity of a tumor antigen |
WO2010088924A1 (en) | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
WO2011068226A1 (ja) * | 2009-12-03 | 2011-06-09 | 株式会社アウレオ | マクロファージ貪食能活性化組成物および/またはマクロファージにおけるサイトカイン産生促進組成物 |
CN101850117B (zh) * | 2010-06-03 | 2012-05-30 | 国家兽用生物制品工程技术研究中心 | 一种复方免疫佐剂及疫苗 |
EP3222621B1 (en) | 2010-08-17 | 2023-03-08 | 3M Innovative Properties Company | Lipidated immune response modifier compound and its medical use |
PT3173427T (pt) | 2011-03-31 | 2019-09-17 | Adc Therapeutics Sa | Anticorpos contra antigénio associado ao rim 1 e fragmentos de ligação a antigénio dos mesmos |
BR112013031039B1 (pt) | 2011-06-03 | 2020-04-28 | 3M Innovative Properties Co | compostos de hidrazino 1h-imidazoquinolina-4-aminas, conjugados feitos destes compostos, composição e composição farmacêutica compreendendo ditos compostos e conjugados, usos dos mesmos e método de fabricação do conjugado |
JP6460789B2 (ja) | 2011-06-03 | 2019-01-30 | スリーエム イノベイティブ プロパティズ カンパニー | ポリエチレングリコールセグメントを有するヘテロ2官能性リンカー及び該リンカーから調製された免疫反応調節複合体 |
NZ625758A (en) | 2012-01-09 | 2016-05-27 | Alethia Biotherapeutics Inc | Method for treating breast cancer |
GB201310578D0 (en) | 2013-06-13 | 2013-07-31 | Univ Nottingham Trent | Electroactive actuators |
EP3033056B1 (en) | 2013-08-12 | 2020-01-15 | 3M Innovative Properties Company | Peptides for enhancing transdermal delivery |
AU2016339033B2 (en) | 2015-10-12 | 2021-04-08 | Reflow Medical, Inc. | Stents having protruding drug-delivery features and associated systems and methods |
WO2017184735A1 (en) * | 2016-04-19 | 2017-10-26 | Ifm Therapeutics, Inc | Nlrp3 modulators |
BR112018071347A2 (pt) | 2016-04-19 | 2019-02-05 | Innate Tumor Immunity Inc | moduladores de nlrp3 |
US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
WO2018217897A1 (en) * | 2017-05-23 | 2018-11-29 | David Weiner | Compositions and method for inducing an immune response |
KR20200051778A (ko) | 2017-09-13 | 2020-05-13 | 사노피 파스퇴르 | 인간 시토메갈로바이러스 면역원성 조성물 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL73534A (en) * | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
IL105325A (en) * | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
JP2002514056A (ja) * | 1996-10-23 | 2002-05-14 | アメリカン・ホーム・プロダクツ・コーポレーション | ワクチン |
GB9818627D0 (en) * | 1998-08-26 | 1998-10-21 | Glaxo Group Ltd | Improvements in dva vaccination |
-
2000
- 2000-09-20 GB GBGB0023008.6A patent/GB0023008D0/en not_active Ceased
-
2001
- 2001-09-20 TW TW090123505A patent/TWI287453B/zh not_active IP Right Cessation
- 2001-09-20 MX MXPA03002453A patent/MXPA03002453A/es active IP Right Grant
- 2001-09-20 MY MYPI20014415A patent/MY138978A/en unknown
- 2001-09-20 CZ CZ2003792A patent/CZ2003792A3/cs unknown
- 2001-09-20 AU AU8790801A patent/AU8790801A/xx active Pending
- 2001-09-20 US US10/380,981 patent/US20040076633A1/en not_active Abandoned
- 2001-09-20 NZ NZ524792A patent/NZ524792A/en not_active IP Right Cessation
- 2001-09-20 IL IL15494701A patent/IL154947A0/xx unknown
- 2001-09-20 KR KR1020037004041A patent/KR100876263B1/ko not_active IP Right Cessation
- 2001-09-20 DE DE60134866T patent/DE60134866D1/de not_active Expired - Lifetime
- 2001-09-20 JP JP2002528295A patent/JP2004509150A/ja active Pending
- 2001-09-20 CN CNB018186173A patent/CN1197620C/zh not_active Expired - Fee Related
- 2001-09-20 AT AT01967535T patent/ATE401097T1/de not_active IP Right Cessation
- 2001-09-20 HU HU0301180A patent/HUP0301180A3/hu unknown
- 2001-09-20 ES ES01967535T patent/ES2309086T3/es not_active Expired - Lifetime
- 2001-09-20 BR BR0113982-7A patent/BR0113982A/pt not_active Application Discontinuation
- 2001-09-20 AR ARP010104453A patent/AR035586A1/es unknown
- 2001-09-20 EP EP01967535A patent/EP1318835B1/en not_active Revoked
- 2001-09-20 WO PCT/GB2001/004207 patent/WO2002024225A1/en active IP Right Grant
- 2001-09-20 AU AU2001287908A patent/AU2001287908B2/en not_active Ceased
- 2001-09-20 PL PL01360895A patent/PL360895A1/xx not_active Application Discontinuation
- 2001-09-20 CA CA002422863A patent/CA2422863A1/en not_active Abandoned
-
2003
- 2003-03-19 NO NO20031274A patent/NO20031274L/no unknown
- 2003-03-20 ZA ZA200302231A patent/ZA200302231B/en unknown
- 2003-11-26 HK HK03108643.1A patent/HK1057700A1/xx not_active IP Right Cessation
-
2007
- 2007-06-19 US US11/764,814 patent/US20070248614A1/en not_active Abandoned
-
2010
- 2010-09-15 US US12/882,470 patent/US20110002953A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR0113982A (pt) | 2003-08-19 |
CN1473051A (zh) | 2004-02-04 |
CZ2003792A3 (cs) | 2004-12-15 |
IL154947A0 (en) | 2003-10-31 |
ATE401097T1 (de) | 2008-08-15 |
EP1318835B1 (en) | 2008-07-16 |
AU8790801A (en) | 2002-04-02 |
NO20031274D0 (no) | 2003-03-19 |
ES2309086T3 (es) | 2008-12-16 |
MXPA03002453A (es) | 2003-06-19 |
CN1197620C (zh) | 2005-04-20 |
HK1057700A1 (en) | 2004-04-16 |
TWI287453B (en) | 2007-10-01 |
EP1318835A1 (en) | 2003-06-18 |
KR100876263B1 (ko) | 2008-12-26 |
NZ524792A (en) | 2004-09-24 |
DE60134866D1 (de) | 2008-08-28 |
ZA200302231B (en) | 2004-05-05 |
US20070248614A1 (en) | 2007-10-25 |
HUP0301180A3 (en) | 2005-11-28 |
HUP0301180A2 (hu) | 2004-03-01 |
NO20031274L (no) | 2003-05-19 |
KR20040023566A (ko) | 2004-03-18 |
US20110002953A1 (en) | 2011-01-06 |
CA2422863A1 (en) | 2002-03-28 |
US20040076633A1 (en) | 2004-04-22 |
AU2001287908B2 (en) | 2005-06-30 |
WO2002024225A1 (en) | 2002-03-28 |
JP2004509150A (ja) | 2004-03-25 |
MY138978A (en) | 2009-08-28 |
GB0023008D0 (en) | 2000-11-01 |
PL360895A1 (en) | 2004-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR035586A1 (es) | Composicion de vacuna, equipo, metodos para incrementar la respuesta inmune, uso de un derivado de 1h-imidazo(4,5-c)quinolin-4-amina en la fabricacion de un medicamento, y combinacion de componentes para la administracion separada, secuencial o concomitante para el uso en la vacunacion de adn | |
Tagliabue et al. | Vaccine adjuvants: the dream becomes real | |
ES2257068T3 (es) | Mezclas de adyuvantes de cpg y saponinas y metodos de empleo de las mismas. | |
Weeratna et al. | CpG DNA induces stronger immune responses with less toxicity than other adjuvants | |
NO20015073D0 (no) | Vaksiner | |
IL260135A (en) | Preparations and methods of neisseria meningitidis | |
NO20010922D0 (no) | FremgangsmÕte for DNA vaksinering | |
BRPI0414381A (pt) | composição de adjuvante, composição ou composições imunogênica(s), composição de vacina, processo para a fabricação de uma composição imunogênica, composição ou composições farmacêutica(s), kit, métodos para tratar um paciente que sofre de, ou que é suscetìvel a, um tumor, para incrementar uma resposta imune de um mamìfero a um antìgeno e para suscitar uma resposta imune em m mamìfero contra um estado de doença, usos de uma imidazoquinolina ou derivado da mesma e gm-csf e dos componentes | |
EA200601761A1 (ru) | Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения | |
ES2185762T3 (es) | Vacunas contra la peste. | |
Beignon et al. | Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG‐containing oligodeoxynucleotide and effective priming of influenza virus‐specific CD4+ T cells | |
JP2005526085A5 (es) | ||
ES2352780A1 (es) | Lipopolisacárido de ochrobactrum intermedium contra la sepsis. | |
CA2466937C (fr) | Antigene mycobacterien recombinant de type hemagglutinine de liaison a l'heparine methylee, procedes de preparation et compositions immunogenes comprenant un tel antigene | |
DE60331412D1 (de) | Hiv-vakzine und anwendungsverfahren | |
AR053661A1 (es) | Peptido para entregar vacunas via mucosas | |
DE60136928D1 (de) | Verwendung von pflanzen-öl-körper in impfstoffverabreichungsysteme | |
Qin et al. | CpG ODN enhances immunization effects of hepatitis B vaccine in aged mice | |
Farnós et al. | The recombinant rabbit hemorrhagic disease virus VP60 protein obtained from Pichia pastoris induces a strong humoral and cell-mediated immune response following intranasal immunization in mice | |
ES2079851T3 (es) | Uso de il-4 para mejorar la respuesta inmunitaria frente a inmunogenos en vacunas. | |
EP2501396B1 (en) | Low antigen-dose immunization for maximizing t-helper cell 1 (th1) immunity against disease | |
Ekström et al. | Iscom and iscom-matrix enhance by intranasal route the IgA responses to OVA and rCTB in local and remote mucosal secretions | |
BR0208980A (pt) | Vacinas incluindo ifn do tipo i como um adjuvante e processos relacionados a esses | |
CN115996751A (zh) | 与离子液体佐剂有关的方法和组合物 | |
AR023536A1 (es) | Vacunas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |